NASDAQ: $ATOS Atossa Therapeutics, Inc. has underscored the continued strategic significance of its lead drug candidate, Z-Endoxifen, for the treatment of Duchenne Muscular Dystrophy (DMD). This reinforcement comes directly on the heels of recent legislative action by the U.S. Congress to reauthorize the Priority Review Voucher (PRV) program. Z-Endoxifen and the Importance of the PRV…